NIH R01 · 2024
Breast Cancer Brain Metastasis Therapy by Focused Ultrasound-Guided Control of HER2 CAR T cells
Project Summary HER2-targeted therapies are promising treatment options for metastatic breast cancer and have improved the median overall survival. However, breast cancer brain metastasis (BCBM), which is observed in up to 50% of HER2-positive breast cancer patients, continues to be a clinical challenge with most patients surviving less than 2 years following CNS involvement. These dismal outcomes underscore the need for new and more effective treatments for BCBM. Chimeric Antigen Receptor (CAR) T cell therapy has led to durable responses in patients with certain types of blood cancers. However, the treatment of brain tumors, such as BCBM, involves a unique set of challenges, including…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.